Hyderabad: US-based biopharma giant Amgen flagged off its first India investment with a new technology and innovation centre in Hyderabad.

The site is expected to accelerate Amgen’s digital capabilities through artificial intelligence and data science to further advance its pipeline of medicines, while creating significant opportunities for local talent.

U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, Chief Executive Officer Robert A. Bradway said at the inauguration of the site.

HYDERABAD: US-based biopharma giant on Monday opened its new technology and innovation centre in Hyderabad with its CEO Robert Bradway announcing a $200 million investment commitment in the facility through 2025 with additional investments planned in future years.

Amgen (NASDAQ: AMGN) is investing $200 million in its new technology and innovation center in Hyderabad, India, to enhance AI and data-driven drug development. CEO Robert Bradway, speaking at the sites inauguration,

Amgen (NASDAQ:AMGN) reportedly plans to invest over $200M in its newly opened technology and innovation center in Hyderabad, India. The site, which was officially opened on Monday, is expected to employ around 2,